HUP1400294A2 - Novel application of clopidogrel - Google Patents

Novel application of clopidogrel

Info

Publication number
HUP1400294A2
HUP1400294A2 HU1400294A HUP1400294A HUP1400294A2 HU P1400294 A2 HUP1400294 A2 HU P1400294A2 HU 1400294 A HU1400294 A HU 1400294A HU P1400294 A HUP1400294 A HU P1400294A HU P1400294 A2 HUP1400294 A2 HU P1400294A2
Authority
HU
Hungary
Prior art keywords
clopidogrel
novel application
novel
application
Prior art date
Application number
HU1400294A
Other languages
Hungarian (hu)
Inventor
Szendrei Levente Dr
Berecz Roland Dr
Original Assignee
Skillpharm Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skillpharm Kft filed Critical Skillpharm Kft
Priority to HU1400294A priority Critical patent/HUP1400294A2/en
Priority to GB1621183.1A priority patent/GB2541348A/en
Priority to PCT/HU2015/000053 priority patent/WO2015189650A1/en
Publication of HUP1400294A2 publication Critical patent/HUP1400294A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
HU1400294A 2014-06-13 2014-06-13 Novel application of clopidogrel HUP1400294A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HU1400294A HUP1400294A2 (en) 2014-06-13 2014-06-13 Novel application of clopidogrel
GB1621183.1A GB2541348A (en) 2014-06-13 2015-06-11 Clopidogrel for use in the treatment of benign prostatic hyperplasia
PCT/HU2015/000053 WO2015189650A1 (en) 2014-06-13 2015-06-11 Clopidogrel for use in the treatment of benign prostatic hyperplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1400294A HUP1400294A2 (en) 2014-06-13 2014-06-13 Novel application of clopidogrel

Publications (1)

Publication Number Publication Date
HUP1400294A2 true HUP1400294A2 (en) 2015-12-28

Family

ID=89991514

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1400294A HUP1400294A2 (en) 2014-06-13 2014-06-13 Novel application of clopidogrel

Country Status (3)

Country Link
GB (1) GB2541348A (en)
HU (1) HUP1400294A2 (en)
WO (1) WO2015189650A1 (en)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (en) 1982-07-13 1986-05-16 Sanofi Sa NOVEL THIENO (3, 2-C) PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATION
FR2623810B2 (en) 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for use in the treatment of benign prostatic hyperplasia
FR2744918B1 (en) 1996-02-19 1998-05-07 Sanofi Sa NEW COMBINATIONS OF ACTIVE INGREDIENTS CONTAINING THIENO (3,2-C) PYRIDINE DERIVATIVE AND AN ANTITHROMBOTIC
ZA991319B (en) 1998-02-20 2000-11-20 Ortho Mcneil Pharm Inc Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
WO1999042488A1 (en) 1998-02-20 1999-08-26 Vanson, Inc. Composition and method for reducing transpiration in plants
FR2779726B1 (en) 1998-06-15 2001-05-18 Sanofi Sa POLYMORPHIC FORM OF CLOPIDOGREL HYDROGENOSULFATE
AU3192700A (en) 1999-03-17 2000-10-04 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions
WO2001030324A2 (en) * 1999-10-27 2001-05-03 Aufsess Joachim G Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
HUP0200438A3 (en) 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
CN1646115B (en) 2002-02-07 2010-06-09 Gtx公司 Use of SARMS in preparing medicine for treating benign prostate hyperplasia
GB2393181A (en) 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
US20040180812A1 (en) 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
DE10305984A1 (en) 2003-02-13 2004-09-02 Helm Ag Salts of organic acids with clopidogrel and their use in the manufacture of pharmaceutical formulations
WO2005070464A2 (en) 2004-01-21 2005-08-04 Biofarma Ilac Sanayi Ve Ticaret A.S. A tablet formulation of clopidogrel bisulphate
AU2005236034A1 (en) 2004-04-20 2005-11-03 Sanofi-Aventis Polymorphic forms of methyl (+) - (S) -alpha- (2-chlorophenyl) -6, 7-dihydrothieno [3,2-c]pyridine-5(4H) acetate hydrobromide, clopidrogel hydrobromide
KR20070009851A (en) 2005-07-14 2007-01-19 씨제이 주식회사 Pharmaceutical compositions containing clopidogrel bisulfate
KR20070044323A (en) 2005-10-24 2007-04-27 에스케이케미칼주식회사 Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
IS2385B (en) 2006-02-10 2008-07-15 Actavis Group Hf. Clopidogrel bisulfate pharmaceutical compositions
ES2342965T5 (en) 2006-04-13 2013-04-03 Acino Pharma Ag Partial glycerides as lubricants for pharmaceutical compositions containing thiena (3,2-c) pyridine derivatives
AT506095A1 (en) 2007-12-03 2009-06-15 Volopharm Gmbh USE OF PROTEASES
ATE530172T1 (en) 2008-02-26 2011-11-15 Lesvi Laboratorios Sl PHARMACEUTICAL FORMULATIONS CONTAINING CLOPIDOGREL
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
WO2014014177A1 (en) 2012-07-18 2014-01-23 조선대학교 산학협력단 Composition comprising dendropanax morbifera extract or compound derived therefrom as active ingredient for preventing and treating benign prostatic hyperplasia

Also Published As

Publication number Publication date
WO2015189650A1 (en) 2015-12-17
GB2541348A (en) 2017-02-15
GB201621183D0 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
IL251584A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL246902B (en) Dihydropyrrolopyridine inhibitors of ror-gamma
SG11201609265RA (en) Characterizing states of subject
IL257026A (en) Solid state forms of eluxadoline
SI3845221T1 (en) Solid state forms of sofosbuvir
GB2522719B (en) Method of manufacture
IL246979A0 (en) Solid state forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
GB201418395D0 (en) Cyclo-depolymerisation of polybutadiene
ZA201608686B (en) Interseparation of metals
GB2522716B (en) Method of manufacture
IL249130B (en) Preparation of piperidine-4-carbothioamide
IL249332A0 (en) Solid state forms of sofosbuvir
HUP1400294A2 (en) Novel application of clopidogrel
GB201412359D0 (en) Composition of objects
GB201412089D0 (en) Composition of objects
GB201417601D0 (en) Articles of manufacture
GB201412053D0 (en) Articles of manufacture
GB201418230D0 (en) Construction of surfaces
GB201406303D0 (en) Production of objects
PL3137475T3 (en) Purification of epidaunorubicin
GB201417347D0 (en) Prodrugs of delanzomib
GB201405157D0 (en) Theory of international law
GB201403170D0 (en) Preparation of antibacterial bisbenzimidazoles
GB201405155D0 (en) Theory of entertainment

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished